A Phase 1 interventional study of SAD, SHR-2004 and SAD, SHR-2004 placebo in Prevention of Arterial and Venous Thrombosis, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Status unknown at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-30.
Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Venous Thrombosis with a site in China — 16 open to participants now, 18 under way, 2 of them phase 3. Venous Thrombosis · China.
Among the 59 studies in Venous Thrombosis with a site in China, this one is the 35th largest by enrollment of the 41 interventional ones that give a count, is one of 11 that started in 2022, is the only one in phase 1, and was the 40th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →16 of the 59 studies in Venous Thrombosis with a site in China are open now. Recruiting first, the newest first:
BrosMed Medical Co., Ltd · Sites in China
Ages 18+
RenJi Hospital · Sites in China
Ages 18–85
Chinese PLA General Hospital · Sites in China
Ages 18–70 · Healthy volunteers
China-Japan Friendship Hospital · Sites in China
Ages 14+
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–100
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 17 · Phase 4 6
First in 2006; this study’s year is marked. 11 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 360 across the 41 interventional studies, 600 across the 17 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing Suncadia Pharmaceuticals Co., Ltd, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Beijing Suncadia Pharmaceuticals Co., Ltd is the lead sponsor of 25 studies on the registry; 9 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 3 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Venous Thrombosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04649489Phase 3Jia FanA Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev | 2027-08-31 |
| NCT05588284Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityPreservation of Venous Valvular Function After PMT for Acute DVT | 2026-12-30 |
| NCT04694248First Affiliated Hospital of Zhejiang UniversityAnticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting | 2026-12-31 |
| NCT05286710RenJi HospitalRheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb | 2026-12-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies in Venous Thrombosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the safety and tolerability of SHR-2004 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-2004 injection in healthy subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 6 cohorts of healthy subjects will receive a single dose of SHR-2004 injection
Drug: SAD, SHR-2004
Up to 6 cohorts of healthy subjects will receive a single dose of SHR-2004 placebo injection
Drug: SAD, SHR-2004 placebo
Ascending dose
Ascending dose
To assess the number of subjects with adverse events (AEs) and serious adverse events (SAEs)
Time frame: up to day 113
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Jan 2023, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Suncadia Pharmaceuticals Co., Ltd →